<DOC>
	<DOCNO>NCT02028065</DOCNO>
	<brief_summary>The purpose study assess potential hypersensitivity symptom upon repeat exposure sugammadex . Healthy participant randomize one three treatment arm : sugammadex 4 mg/kg , sugammadex 16 mg/kg placebo . Participants receive 3 single intravenous ( IV ) dose randomized treatment , approximately 5-week washout Dose 1 Dose 2 Dose 2 Dose 3 . Participants confine study center day dose completion 24-hour post dose assessment .</brief_summary>
	<brief_title>A Study Evaluate Incidence Hypersensitivity After Administration Sugammadex Healthy Participants ( MK-8616-101 )</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Anaphylaxis</mesh_term>
	<criteria>Male nonpregnant nonbreast feed female Females childbearing potential must serum βhuman chorionic gonadotropin ( βhCG ) level consistent nonpregnant state agree use ( and/or partner use ) two acceptable method birth control begin screening , throughout trial ( include washout interval treatment period ) poststudy followup visit Females childbearing potential must either ) postmenopausal ( menstrual period least 1 year follicle stimulate hormone [ FSH ] value postmenopausal range ) b ) surgically sterile ( i.e. , hysterectomy , oophorectomy tubal ligation ) In good health base medical history , laboratory test assessment Body Mass Index ( BMI ) ≥19 ≤32 kg/m^2 Nonsmoker smoke ≤10 cigarettes/day equivalent ( 2 pipes/day , 1 cigar/day ) agree smoke confine study center Mentally legally incapacitate , significant emotional problem time screen visit expect conduct trial history clinically significant psychiatric disorder last 5 year History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological abnormality diseases History cancer ( malignancy ) History significant multiple and/or severe allergy ( e.g. , food , drug , latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) Has major surgery and/or donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior screen Has participate another investigational trial within 4 week prior screen Is unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy begin approximately 2 week prior administration initial dose trial drug , throughout trial ( include washout interval treatment period ) , poststudy followup visit Has receive subcutaneous sublingual immunotherapy within past 1 year Consumes &gt; 3 glass alcoholic beverage per day Consumes excessive amount , define &gt; 6 serving coffee , tea , cola , energy drink , caffeinated beverage per day Currently regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 12 month Has recollection previously receive sugammadex , Bridion™ , SCH 900616 , ORG 25969 , MK8616 History chronic urticaria angioedema Is immediate family member ( spouse child ) member investigational site sponsor staff directly involve trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>reversal neuromuscular blockade</keyword>
</DOC>